This article discusses a new approach in the treatment of multi-drug resistant HIV (MDR-HIV). Get ready for some links. It's a biologic medication, called Ibalizumab. A biologic is a pharmaceutical produced by synthesizing living materials for a medical application. This particular medication has been in development since the early 2000's. This antibody was humanized via a mouse. It binds the CD4, which is affected by HIV.
It's estimated, out of the million + people being treated for HIV in the USA, over 10,000 have MDR-HIV. This approach may only help a small population at this time, but it's a step. This drug is administered every 2 weeks intravenously.
This shows how busy the researchers have been over the last several decades. Unfortunately, it isn't a quick process. Even now, it could be years, before this medication is widely available. That's if everything goes well. Even if it fails, the research will be invaluable.
Cya...